Breast cancer bone metastasis: Difference between revisions
Jump to navigation
Jump to search
Jack Khouri (talk | contribs) |
Jack Khouri (talk | contribs) |
||
| Line 1: | Line 1: | ||
==Overview== | ==Overview== | ||
Bone is the most common site of breast cancer recurrence <ref name="pmid17062708">{{cite journal| author=Coleman RE| title=Clinical features of metastatic bone disease and risk of skeletal morbidity. | journal=Clin Cancer Res | year= 2006 | volume= 12 | issue= 20 Pt 2 | pages= 6243s-6249s | pmid=17062708 | doi=10.1158/1078-0432.CCR-06-0931 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17062708 }} </ref>, <ref name="pmid3814476">{{cite journal| author=Coleman RE, Rubens RD| title=The clinical course of bone metastases from breast cancer. | journal=Br J Cancer | year= 1987 | volume= 55 | issue= 1 | pages= 61-6 | pmid=3814476 | doi= | pmc=PMC2001575 | url= }} </ref>. Despite modern cancer therapy, up to two thirds of patients with bone metastasis will subsequently develop an skeletal-related event (sre), defined as any of pathologic fracture, a requirement for surgical intervention and palliative radiotherapy to bone lesions, hypercalcemia of malignancy, and spinal cord compression. Not only are sres associated with significant morbidity, they also negatively affect survival. Moreover, sres are associated with loss of mobility and social functioning, and reduction in quality of life. | Bone is the most common site of breast cancer recurrence <ref name="pmid17062708">{{cite journal| author=Coleman RE| title=Clinical features of metastatic bone disease and risk of skeletal morbidity. | journal=Clin Cancer Res | year= 2006 | volume= 12 | issue= 20 Pt 2 | pages= 6243s-6249s | pmid=17062708 | doi=10.1158/1078-0432.CCR-06-0931 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17062708 }} </ref>, <ref name="pmid3814476">{{cite journal| author=Coleman RE, Rubens RD| title=The clinical course of bone metastases from breast cancer. | journal=Br J Cancer | year= 1987 | volume= 55 | issue= 1 | pages= 61-6 | pmid=3814476 | doi= | pmc=PMC2001575 | url= }} </ref>. Despite modern cancer therapy, up to two thirds of patients with bone metastasis will subsequently develop an skeletal-related event (sre), defined as any of pathologic fracture, a requirement for surgical intervention and palliative radiotherapy to bone lesions, hypercalcemia of malignancy, and spinal cord compression. Not only are sres associated with significant morbidity, they also negatively affect survival. Moreover, sres are associated with loss of mobility and social functioning, and reduction in quality of life. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 21:46, 22 November 2011
Overview
Bone is the most common site of breast cancer recurrence [1], [2]. Despite modern cancer therapy, up to two thirds of patients with bone metastasis will subsequently develop an skeletal-related event (sre), defined as any of pathologic fracture, a requirement for surgical intervention and palliative radiotherapy to bone lesions, hypercalcemia of malignancy, and spinal cord compression. Not only are sres associated with significant morbidity, they also negatively affect survival. Moreover, sres are associated with loss of mobility and social functioning, and reduction in quality of life.
References
- ↑ Coleman RE (2006). "Clinical features of metastatic bone disease and risk of skeletal morbidity". Clin Cancer Res. 12 (20 Pt 2): 6243s–6249s. doi:10.1158/1078-0432.CCR-06-0931. PMID 17062708.
- ↑ Coleman RE, Rubens RD (1987). "The clinical course of bone metastases from breast cancer". Br J Cancer. 55 (1): 61–6. PMC 2001575. PMID 3814476.